Description

Berry Genomics Co.,Ltd is a prominent genomics firm dedicated to advancing and commercializing cutting-edge technologies for both life sciences research and clinical applications across China. Its diverse portfolio includes next-generation sequencing (NGS)-based diagnostic solutions designed to detect a wide array of genetic diseases and cancers, spanning from the preconception stage through adulthood. Beyond general NGS offerings, Berry Genomics provides specialized genomic analyses such as Whole Exome Sequencing (WES) for identifying inherited pathogenic mutations, particularly in the GCH1 gene linked to Dopa-responsive dystonia. They also utilize CNV-Seq tests to pinpoint chromosomal translocations on chromosomes 2 and 8, and offer Whole Genome Sequencing (WGS) for comprehensive, genome-wide identification of DNA variations like SNPs, CNVs, Indels, and SVs. For more specific research needs, they provide RNA-Seq, including studies on the photo-induced protein dimerization in plant cryptochromes. The company's extensive client base encompasses approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. Furthermore, it caters to a broad spectrum of organizations, including research institutions, universities, and corporate entities. In addition, Berry Genomics maintains a strategic partnership with Personalis, Inc. Established in 2010, the company's headquarters are situated in Beijing, China.